Literature DB >> 9097802

Systemic immunosuppressive therapy and the occurrence of malignancy in patients with ocular inflammatory disease.

L Lane1, R Tamesis, A Rodriguez, W Christen, Y A Akova, E Messmer, M Pedroza-Seres, N Barney, C S Foster.   

Abstract

PURPOSE: To compare the occurrence of malignancy in patients with severe ocular inflammatory disease treated with systemic corticosteroids alone or with systemic immunosuppressive drugs with or without systemic corticosteroids.
METHODS: The clinical records of 543 patients with ocular inflammatory disease treated with systemic corticosteroids and/or immunosuppressive chemotherapy were reviewed in a retrospective cohort study. Characteristics of patients treated with corticosteroids alone were compared with characteristics of patients treated with immunosuppressive agents with or without preceding corticosteroid treatment. The rates of malignancy after initiation of drug therapy were compared using an exact test for incidence rate data.
RESULTS: Compared with patients treated with corticosteroids alone, patients treated with immunosuppressants with or without corticosteroid treatment were older and had more severe systemic disease. During a total of 1261 person-years of follow-up, a malignancy developed in five patients. The rate of malignancy in the immunosuppressant group (4 malignancies during 968 person-years of follow-up) was not significantly different from the rate in the corticosteroids alone group (1 malignancy during 293 person-years of follow-up) (P > 0.90, exact test for incidence rate data).
CONCLUSION: These findings do not support the hypothesis of an increased risk of malignancy in patients with severe ocular inflammatory disease who are treated with systemic immunosuppressive agents compared with patients treated with systemic corticosteroids.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 9097802     DOI: 10.1016/s0161-6420(95)30835-4

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  7 in total

Review 1.  Pharmacotherapy of scleritis: current paradigms and future directions.

Authors:  Robert M Beardsley; Eric B Suhler; James T Rosenbaum; Phoebe Lin
Journal:  Expert Opin Pharmacother       Date:  2013-02-21       Impact factor: 3.889

2.  Long-term risk of malignancy among patients treated with immunosuppressive agents for ocular inflammation: a critical assessment of the evidence.

Authors:  John H Kempen; Sapna Gangaputra; Ebenezer Daniel; Grace A Levy-Clarke; Robert B Nussenblatt; James T Rosenbaum; Eric B Suhler; Jennifer E Thorne; C Stephen Foster; Douglas A Jabs; Kathy J Helzlsouer
Journal:  Am J Ophthalmol       Date:  2008-06-25       Impact factor: 5.258

3.  Cyclosporin A therapy in refractory non-infectious childhood uveitis.

Authors:  D J Kilmartin; J V Forrester; A D Dick
Journal:  Br J Ophthalmol       Date:  1998-07       Impact factor: 4.638

Review 4.  [Mucous membrane pemphigoid with ocular involvement. Part II: therapy].

Authors:  T Meyer-ter-Vehn; E Schmidt; D Zillikens; G Geerling
Journal:  Ophthalmologe       Date:  2008-04       Impact factor: 1.059

5.  Oral voclosporin: novel calcineurin inhibitor for treatment of noninfectious uveitis.

Authors:  Martin Roesel; Christoph Tappeiner; Arnd Heiligenhaus; Carsten Heinz
Journal:  Clin Ophthalmol       Date:  2011-09-13

Review 6.  Treating rheumatic patients with a malignancy.

Authors:  Katarzyna Elandt; Daniel Aletaha
Journal:  Arthritis Res Ther       Date:  2011-06-29       Impact factor: 5.156

7.  Are patients with inflammatory eye disease treated with systemic immunosuppressive therapy at increased risk of malignancy?

Authors:  William B Yates; Peter J McCluskey; Denis Wakefield
Journal:  J Ophthalmic Inflamm Infect       Date:  2013-05-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.